US 11,702,401 B2
Compounds and methods of use
Roopa Rai, San Francisco, CA (US); Sarvajit Chakravarty, San Francisco, CA (US); Brahmam Pujala, Noida (IN); Bharat Uttam Shinde, Noida (IN); Anjan Kumar Nayak, Noida (IN); Anil Kumar Agarwal, Noida (IN); Sreekanth A. Ramachandran, Noida (IN); and Son Minh Pham, San Francisco, CA (US)
Assigned to Medivation Technologies LLC, New York, NY (US)
Filed by Medivation Technologies LLC, New York, NY (US)
Filed on May 22, 2021, as Appl. No. 17/327,705.
Application 17/327,705 is a continuation of application No. 16/659,775, filed on Oct. 22, 2019, granted, now 11,053,216.
Application 16/659,775 is a continuation of application No. 15/933,532, filed on Mar. 23, 2018, granted, now 10,501,436, issued on Dec. 10, 2019.
Application 15/933,532 is a continuation of application No. 15/109,013, granted, now 10,030,004, issued on Jul. 24, 2018, previously published as PCT/US2014/072922, filed on Dec. 31, 2014.
Claims priority of application No. 6/DEL/2014 (IN), filed on Jan. 1, 2014.
Prior Publication US 2022/0000847 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); C07D 213/72 (2006.01); C07D 213/73 (2006.01); C07D 213/82 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); A61K 31/4439 (2006.01); A61K 31/4709 (2006.01); A61K 31/506 (2006.01); C07D 487/04 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 213/72 (2013.01); C07D 213/73 (2013.01); C07D 213/82 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)] 26 Claims
 
1. A method of treating a tumor in an individual diagnosed with cancer, comprising administering to the individual an effective amount of

OG Complex Work Unit Chemistry
4-(2-(5-chloro-2-fluorophenyl)-5-isopropylpyridin-4-ylamino)-N-(1,3-dihydroxypropan-2-yl)nicotinamide or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of colon cancer, liver cancer, thyroid cancer, endometroid cancer, gallbladder cancer, kidney cancer, adrenocortical cancer, skin cancer, head and neck cancer and sarcoma.